CRISPR Therapeutics AG

Market cap: $5,049,357,255

Exchange: NAS

Sector: Health Technology

Share
Tweet

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Key Statistics

Company Name

CRISPR Therapeutics AG

Average Volume (10 days)

1,295,191

Average Volume (30 days)

1,349,640

Moving Average (50 days)

$76.04

Moving Average (200 days)

$62.59

Ex-Divided Date

n/a

Dividend Yield

0

P/E Ratio

-32.8713

Market Cap

5,049,357,255

Shares Outstanding

80,275,950

52-Week High Split Adjust Only

91.1

52-Week Low Split Adjust Only

37.55

Employee Count

304

Beta

0

Next Earnings Date

2024-05-06

TTM Dividend Rate Per Share

0

Price Changes

Past 5 days

-0.08%

Past 30 days

-0.21%

Past 3 months

0.04%

Past 6 months

0.46%

Past year

0.39%

Past 2 years

-0.02%

Past 5 years

0.64%

Max % Change

3.46%

PEER GROUP COMPARATIVE PERFORMANCE

NameTickerPrice/Sales (ttm)Price/Book (ttm)Forward P/EPEG RatioEV/Revenue
CRISPR Therapeutics AGCRSP8132.954.96-144.88132.956492.43
Peer AvgN/An/an/a-13.3n/an/a
Ocular Therapeutix IncOCULn/an/a-19.1n/an/a
Olema Pharmaceuticals IncOLMAn/an/a-21.2n/an/a
Oncocyte CorporationOCXn/an/a-13.1n/an/a
Oragenics Inc.OGENn/an/an/an/an/a